Terminated PHASE2 INTERVENTIONAL NCT00381693

Azacitidine in Treating Patients With Myelofibrosis

Phase II Study of Azacitidine in Myelofibrosis

Sponsor: Mayo Clinic

Conditions Chronic Myeloproliferative Disorders Secondary Myelofibrosis

Interventions azacitidine

Updated 6 times since 2017 Last updated: Apr 19, 2011 Started: Aug 31, 2006 Primary completion: Mar 31, 2008 Completion: Apr 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Due to lack of accrual and trial has demonstrated too little clinical benefit

Other terminated trials from Mayo Clinic

See all terminations from Mayo Clinic

Other Chronic Myeloproliferative Disorders trials with similar outcome

Browse all Chronic Myeloproliferative Disorders trials

This PHASE2 trial investigates Chronic Myeloproliferative Disorders and Secondary Myelofibrosis and is currently terminated or withdrawn. Mayo Clinic leads this study, which shows 6 recorded versions since 2006 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Terminated PHASE2

First recorded

Aug 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Mayo Clinic
National Cancer Institute (NCI)

Data source: Mayo Clinic

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Rochester, United States
• Scottsdale, United States